Abstracts tagged "takayasu arteritis and ultrasonography"

Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Ali Hakim Shoushtari⁷ and Larry W. Moreland⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
Abstract Number: 219 • 2013 ACR/ARHP Annual Meeting
Contrast-Enhanced Ultrasound Of The Sovraortic Arteries: The Potential Role In Monitoring Disease Activity and Response To Treatment In Large Vessel Vasculitis
Giuseppe Germanò¹, Pierluigi Macchioni¹, Niccolò Possemato² and Carlo Salvarani³, ¹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ³Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: promising data has been recently published about the role of contrast-enhanced ultrasound (CEU) in the diagnosis and follow up of Takayasu arteritis (TA) -1,2-…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].